Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

计划入组 40 人 · 首次发布于 2025 年 5 月 13 日

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

计划入组 2 人 · 首次发布于 2020 年 1 月 13 日

Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

计划入组 50 人 · 首次发布于 2026 年 5 月 6 日

Zilucoplan(Zilbrysq)

C₁₇₂H₂₇₈N₂₄O₅₅

anti-LAG-3/anti-TIGIT mAb

anti-viral compound

Novel Anti-Infective Technologies, LLC

AiCuris Anti-Infective Cures AG

Germany

AGENCE REGIONALE DE SANTE DE LA REUNION

Reunion

Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis

Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies

Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment